Distressed asset sale Eiger is navigating Chapter 11 bankruptcy with asset sales already occurring, presenting an opportunity to engage through potential partnerships or acquisition discussions with buyers or lenders who may be evaluating strategic assets such as avexitide and related IP.

Licensing potential Lead asset avexitide holds Breakthrough Therapy designation for post-bariatric hypoglycemia, suggesting potential for collaboration with larger biopharma or specialty pharma companies seeking to expand rare disease portfolios under licensing or co-development deals.

Rare disease focus Eiger targets rare metabolic disorders with a first-in-class GLP-1 antagonist, indicating a niche high-value space where collaborators in endocrinology, rare diseases, or pediatric metabolism could partner on development, manufacturing, or commercial support.

Strategic buyers Recent asset disposition to Amylyx signals a market for strategic buyers or private equity with interest in mid-stage assets; sales conversations could be positioned around asset packages, residual programs, or pipeline optimization opportunities.

Clinical and partnerships upside Beyond avexitide, Eiger’s exploration of peginterferon lambda for hepatitis delta and other programs creates cross-portfolio collaboration opportunities with CROs, contract development manufacturers, or platform technology providers seeking integration into rare-disease trial ecosystems.